Supplementary Tables S1-S15 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Supplemental Table S1. Genome-wide RNAi toxicity screen z-scores, related to Supplemental Figure S1, Supplemental Table S2. Percent DNA copy number gain in melanoma tumor samples compared to normal skin, related to Supplemental Figure S1, Supplemental Table S3. Melanoma panel siRNA toxicity, related to Supplemental Figure S1, Supplemental Table S4. Whole genome transcript profiles, related to Supplemental Figure S1, Supplemental Table S5. GISTIC analysis and expression correlation of candidate melanoma hits, related to Supplemental Figure S1, Supplemental Table S6. SOX10 ChIPSeq, related to Supplemental Figure S3, Supplemental Table S7. SOX10 ChIPSeq motif targets, related to Supplemental Figure S3, Supplemental Table S8. SOX10 ChIPSeq motif targets hypergeometric distribution analysis, related to Supplemental Figure S3, Supplemental Table S9. Whole genome transcript arrays with siRNAs, related to Supplemental Figure S3, Supplemental Table S10. Candidate SOX10 targets, related to Supplemental Figure S3, Supplemental Table S11. Expression correlations in patient samples, related to Supplemental Figure S3, Supplemental Table S12. Elastic net prediction scores, related to Figures 1, 2 and 3, Supplemental Figures S4, S5 and S7, Supplemental Table S13. Elastic net prediction scores, related to Figure 2, Supplemental Table S14. S2N analysis of gene transcripts between TBK1i-sensitive and -resistant BRAF wild-type melanoma cell lines, related to Figure 3, Supplemental Table S15. TMT-phosphoproteomics peptide quantification, related to Figure S12.

补充表 S1：全基因组 RNAi 毒性筛选 z 分数，与补充图 S1 相关；补充表 S2：与正常皮肤相比，黑色素瘤肿瘤样本中 DNA 复制数增加的百分比，与补充图 S1 相关；补充表 S3：黑色素瘤 siRNA 靶向毒性，与补充图 S1 相关；补充表 S4：全基因组转录组图谱，与补充图 S1 相关；补充表 S5：候选黑色素瘤基因击中的 GISTIC 分析及表达相关性，与补充图 S1 相关；补充表 S6：SOX10 ChIPSeq，与补充图 S3 相关；补充表 S7：SOX10 ChIPSeq 模式靶标，与补充图 S3 相关；补充表 S8：SOX10 ChIPSeq 模式靶标超几何分布分析，与补充图 S3 相关；补充表 S9：全基因组转录组 siRNA 测序，与补充图 S3 相关；补充表 S10：候选 SOX10 靶标，与补充图 S3 相关；补充表 S11：患者样本中的表达相关性，与补充图 S3 相关；补充表 S12：弹性网络预测得分，与图 1、2 和 3 以及补充图 S4、S5 和 S7 相关；补充表 S13：弹性网络预测得分，与图 2 相关；补充表 S14：TBK1i 敏感和耐药 BRAF 野生型黑色素瘤细胞系之间基因转录本 S2N 分析，与图 3 相关；补充表 S15：TMT 磷蛋白组学肽定量，与补充图 S12 相关。